

ZD6126 BIBLIOGRAPHY (Updated September 8th, 2008)

1. Siemann, D. W., and Rojiani, A. M. (2002) Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. *Int J Radiat Oncol Biol Phys* **54**, 1512-1517
2. Blakey, D. C., Ashton, S. E., Westwood, F. R., Walker, M., and Ryan, A. J. (2002) ZD6126: a novel small molecule vascular targeting agent. *Int J Radiat Oncol Biol Phys* **54**, 1497-1502
3. Davis, P. D., Dougherty, G. J., Blakey, D. C., Galbraith, S. M., Tozer, G. M., Holder, A. L., Naylor, M. A., Nolan, J., Stratford, M. R., Chaplin, D. J., and Hill, S. A. (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. *Cancer Res* **62**, 7247-7253
4. Goto, H., Yano, S., Zhang, H., Matsumori, Y., Ogawa, H., Blakey, D. C., and Sone, S. (2002) Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. *Cancer Res* **62**, 3711-3715
5. Blakey, D. C., Westwood, F. R., Walker, M., Hughes, G. D., Davis, P. D., Ashton, S. E., and Ryan, A. J. (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. *Clin Cancer Res* **8**, 1974-1983
6. Siemann, D. W., and Rojiani, A. M. (2002) Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. *Int J Radiat Oncol Biol Phys* **53**, 164-171
7. Siemann, D. W., and Horsman, M. R. (2002) Enhancement of radiation therapy by vascular targeting agents. *Curr Opin Investig Drugs* **3**, 1660-1665
8. Goertz, D. E., Yu, J. L., Kerbel, R. S., Burns, P. N., and Foster, F. S. (2002) High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. *Cancer Res* **62**, 6371-6375
9. Micheletti, G., Poli, M., Borsotti, P., Martinelli, M., Imberti, B., Taraboletti, G., and Giavazzi, R. (2003) Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. *Cancer Res* **63**, 1534-1537
10. Herbst, R. S., and O'Reilly, M. S. (2003) The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. *Semin Oncol* **30**, 113-123
11. Shepherd, F. A., and Sridhar, S. S. (2003) Angiogenesis inhibitors under study for the treatment of lung cancer. *Lung Cancer* **41 Suppl 1**, S63-72
12. Sridhar, S. S., and Shepherd, F. A. (2003) Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. *Lung Cancer* **42 Suppl 1**, S81-91
13. Yano, S., Goto, H., Yamamoto, A., Kanematsu, T., and Sone, S. (2003) Angiogenesis in the progression of lung cancer. *Intern Med* **42**, 305-309
14. Thorpe, P. E., Chaplin, D. J., and Blakey, D. C. (2003) The first international conference on vascular targeting: meeting overview. *Cancer Res* **63**, 1144-1147

15. Robinson, S. P., McIntyre, D. J., Checkley, D., Tessier, J. J., Howe, F. A., Griffiths, J. R., Ashton, S. E., Ryan, A. J., Blakey, D. C., and Waterton, J. C. (2003) Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. *Br J Cancer* **88**, 1592-1597
16. Horsman, M. R., and Murata, R. (2003) Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. *Int J Radiat Oncol Biol Phys* **57**, 1047-1055
17. Varghese, H. J., Mackenzie, L. T., Groom, A. C., Ellis, C. G., Ryan, A., MacDonald, I. C., and Chambers, A. F. (2004) In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. *Angiogenesis* **7**, 157-164
18. Soltau, J., and Drevs, J. (2004) ZD-6126 AstraZeneca. *IDrugs* **7**, 380-387
19. Raben, D., Bianco, C., Damiano, V., Bianco, R., Melisi, D., Mignogna, C., D'Armiento, F. P., Cionini, L., Bianco, A. R., Tortora, G., Ciardiello, F., and Bunn, P. (2004) Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. *Mol Cancer Ther* **3**, 977-983
20. McCarty, M. F., Takeda, A., Stoeltzing, O., Liu, W., Fan, F., Reinmuth, N., Akagi, M., Bucana, C., Mansfield, P. F., Ryan, A., and Ellis, L. M. (2004) ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. *Br J Cancer* **90**, 705-711
21. Thorpe, P. E. (2004) Vascular targeting agents as cancer therapeutics. *Clin Cancer Res* **10**, 415-427
22. Horner, S. A., Gould, S., Noakes, J. P., Rattray, N. J., Allen, S. L., Zotova, E., and Arezzo, J. C. (2004) Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat. *Mol Cancer Ther* **3**, 783-791
23. Evelhoch, J. L., LoRusso, P. M., He, Z., DelProposto, Z., Polin, L., Corbett, T. H., Langmuir, P., Wheeler, C., Stone, A., Leadbetter, J., Ryan, A. J., Blakey, D. C., and Waterton, J. C. (2004) Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. *Clin Cancer Res* **10**, 3650-3657
24. Siemann, D. W., Chaplin, D. J., and Horsman, M. R. (2004) Vascular-targeting therapies for treatment of malignant disease. *Cancer* **100**, 2491-2499
25. McIntyre, D. J., Robinson, S. P., Howe, F. A., Griffiths, J. R., Ryan, A. J., Blakey, D. C., Peers, I. S., and Waterton, J. C. (2004) Single dose of the antivascular agent, ZD6126 (N-acetylcolchicol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. *Neoplasia* **6**, 150-157
26. Masunaga, S., Sakurai, Y., Suzuki, M., Nagata, K., Maruhashi, A., Kinash, Y., and Ono, K. (2004) Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy. *Int J Radiat Oncol Biol Phys* **60**, 920-927

27. Goto, H., Yano, S., Matsumori, Y., Ogawa, H., Blakey, D. C., and Sone, S. (2004) Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. *Clin Cancer Res* **10**, 7671-7676
28. Siemann, D. W., and Shi, W. (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. *Int J Radiat Oncol Biol Phys* **60**, 1233-1240
29. Taraboletti, G., Micheletti, G., Dossi, R., Borsotti, P., Martinelli, M., Fiordaliso, F., Ryan, A. J., and Giavazzi, R. (2005) Potential antagonism of tubulin-binding anticancer agents in combination therapies. *Clin Cancer Res* **11**, 2720-2726
30. Masunaga, S., Nagasawa, H., Uto, Y., Hori, H., Ohnishi, K., Takahashi, A., Ohnishi, T., Suzuki, M., Nagata, K., Kinashi, Y., and Ono, K. (2005) Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells. *Oncol Rep* **14**, 393-400
31. Wachsberger, P. R., Burd, R., Marero, N., Daskalakis, C., Ryan, A., McCue, P., and Dicker, A. P. (2005) Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. *Clin Cancer Res* **11**, 835-842
32. Siemann, D. W., and Rojiani, A. M. (2005) The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. *Int J Radiat Oncol Biol Phys* **62**, 846-853
33. Cooney, M. M., Ortiz, J., Bukowski, R. M., and Remick, S. C. (2005) Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. *Curr Oncol Rep* **7**, 90-95
34. Robinson, S. P., Kalber, T. L., Howe, F. A., McIntyre, D. J., Griffiths, J. R., Blakey, D. C., Whittaker, L., Ryan, A. J., and Waterton, J. C. (2005) Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. *Neoplasia* **7**, 466-474
35. Beaudry, P., Force, J., Naumov, G. N., Wang, A., Baker, C. H., Ryan, A., Soker, S., Johnson, B. E., Folkman, J., and Heymach, J. V. (2005) Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. *Clin Cancer Res* **11**, 3514-3522
36. Raben, D., and Ryan, A. (2005) Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005? *Clin Lung Cancer* **7**, 175-179
37. Shi, W., and Siemann, D. W. (2005) Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. *In Vivo* **19**, 1045-1050
38. Kleespies, A., Kohl, G., Friedrich, M., Ryan, A. J., Barge, A., Jauch, K. W., and Bruns, C. J. (2005) Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models. *Neoplasia* **7**, 957-966
39. Bredahl, T., Nielsen, F. U., Stodkilde-Jorgensen, H., Maxwell, R. J., and Horsman, M. R. (2006) The effects of the vascular disrupting agents combretastatin A-4 disodium

phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS. *Acta Oncol* **45**, 306-316

40. Beerepoot, L. V., Radema, S. A., Witteveen, E. O., Thomas, T., Wheeler, C., Kempin, S., and Voest, E. E. (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. *J Clin Oncol* **24**, 1491-1498
41. van Heeckeren, W. J., Bhakta, S., Ortiz, J., Duerk, J., Cooney, M. M., Dowlati, A., McCrae, K., and Remick, S. C. (2006) Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? *J Clin Oncol* **24**, 1485-1488
42. Hoang, T., Huang, S., Armstrong, E., Eickhoff, J. C., and Harari, P. M. (2006) Augmentation of radiation response with the vascular targeting agent ZD6126. *Int J Radiat Oncol Biol Phys* **64**, 1458-1465
43. Shaked, Y., Bertolini, F., Emmenegger, U., Lee, C. R., and Kerbel, R. S. (2006) On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. *J Clin Oncol* **24**, 4040; author reply 4040-4040; author reply 4041
44. Skliarenko, J. V., Lunt, S. J., Gordon, M. L., Vitkin, A., Milosevic, M., and Hill, R. P. (2006) Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. *Cancer Res* **66**, 2074-2080
45. O'Reilly, M. S. (2006) Radiation combined with antiangiogenic and antivascular agents. *Semin Radiat Oncol* **16**, 45-50
46. Madhu, B., Waterton, J. C., Griffiths, J. R., Ryan, A. J., and Robinson, S. P. (2006) The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. *Neoplasia* **8**, 560-567
47. Cullis, E. R., Kalber, T. L., Ashton, S. E., Cartwright, J. E., Griffiths, J. R., Ryan, A. J., and Robinson, S. P. (2006) Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. *Microvasc Res* **71**, 76-84
48. Bozec, A., Lassalle, S., Gugenheim, J., Fischel, J. L., Formento, P., Hofman, P., and Milano, G. (2006) Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. *Br J Cancer* **95**, 722-728
49. Hinnen, P., and Eskens, F. A. (2007) Vascular disrupting agents in clinical development. *Br J Cancer* **96**, 1159-1165
50. Gamrekelashvili, J., Kruger, C., von Wasielewski, R., Hoffmann, M., Huster, K. M., Busch, D. H., Manns, M. P., Korangy, F., and Greten, T. F. (2007) Necrotic tumor cell death in vivo impairs tumor-specific immune responses. *J Immunol* **178**, 1573-1580
51. Lenz, E. M., D'Souza, R. A., Jordan, A. C., King, C. D., Smith, S. M., Phillips, P. J., McCormick, A. D., and Roberts, D. W. (2007) HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126. *J Pharm Biomed Anal* **43**, 1065-1077

52. Masunaga, S., Nagasawa, H., Nagata, K., Suzuki, M., Uto, Y., Hori, H., Kinashi, Y., and Ono, K. (2007) Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells. *J Cancer Res Clin Oncol* **133**, 47-55
53. Cai, S. X. (2007) Small molecule vascular disrupting agents: potential new drugs for cancer treatment. *Recent Patents Anticancer Drug Discov* **2**, 79-101
54. Lippert, J. W. r. (2007) Vascular disrupting agents. *Bioorg Med Chem* **15**, 605-615
55. Vogel-Claussen, J., Gimi, B., Artemov, D., and Bhujwalla, Z. M. (2007) Diffusion-Weighted and Macromolecular Contrast Enhanced MRI of Tumor Response to Antivascular Therapy with ZD6126. *Cancer Biol Ther* **6**,
56. D'Souza, R. A., Partridge, E. A., Roberts, D. W., Ashton, S., Ryan, A., Patterson, A. B., Wilson, Z., and Thurrell, C. C. (2007) Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (¹⁴C-ZD6126) to tumour-bearing mice. *Xenobiotica* **37**, 328-340
57. Bradley, D. P., Tessier, J. J., Ashton, S. E., Waterton, J. C., Wilson, Z., Worthington, P. L., and Ryan, A. J. (2007) Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. *Neoplasia* **9**, 382-391
58. Robinson, S. P., Howe, F. A., Griffiths, J. R., Ryan, A. J., and Waterton, J. C. (2007) Susceptibility Contrast Magnetic Resonance Imaging Determination of Fractional Tumor Blood Volume: A Noninvasive Imaging Biomarker of Response to the Vascular Disrupting Agent ZD6126. *Int J Radiat Oncol Biol Phys* **69**, 872-879
59. Gould, S., Westwood, F. R., Curwen, J. O., Ashton, S. E., Roberts, D. W., Lovick, S. C., and Ryan, A. J. (2007) Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. *J Natl Cancer Inst* **99**, 1724-1728
60. Mocanu, J. D., Yip, K. W., Skliarenko, J., Shi, W., Busson, P., Lo, K. W., Bastianutto, C., and Liu, F. F. (2007) Imaging and Modulating Antisense Microdistribution in Solid Human Xenograft Tumor Models. *Clin Cancer Res* **13**, 5935-5941
61. Martinelli, M., Bonezzi, K., Riccardi, E., Kuhn, E., Frapolli, R., Zucchetti, M., Ryan, A. J., Taraboletti, G., and Giavazzi, R. (2007) Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. *Br J Cancer* **97**, 888-894
62. McCormick, A. D., Slamon, D. L., Lenz, E. M., Phillips, P. J., King, C. D., McKillop, D., and Roberts, D. W. (2007) In vitro metabolism of a tricyclic alkaloid (M445526) in human liver microsomes and hepatocytes. *Xenobiotica* **37**, 972-985
63. Giavazzi, R., Bani, M. R., and Taraboletti, G. (2007) Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. *Cancer Metastasis Rev* **26**, 481-488
64. Partridge, E. A., D'souza, R. A., Lenz, E. M., Smith, S. M., Clarkson-Jones, J., and Roberts, D. W. (2008) Disposition and metabolism of the colchicine derivative [(¹⁴C)-ZD6126 in rat and dog. *Xenobiotica* **38**, 399-421

65. Lorusso, P. M., Gadgeel, S. M., Wozniak, A., Barge, A. J., Jones, H. K., Delproposto, Z. S., Deluca, P. A., Evelhoch, J. L., Boerner, S. A., and Wheeler, C. (2008) Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. *Invest New Drugs* **26**, 159-167
66. Valentini, G., D'Andrea, C., Ferrari, R., Pifferi, A., Cubeddu, R., Martinelli, M., Natoli, C., Ubezio, P., and Giavazzi, R. (2008) In vivo measurement of vascular modulation in experimental tumors using a fluorescent contrast agent. *Photochem Photobiol* **84**, 1249-1256